Gastroesophageal Junction Cancer
📧 Sign up to get email alerts when something new happens for Gastroesophageal Junction Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-05-31Clinical Trial Update: Retrospective Evaluation of Nivolumab in Adjuvant Esophageal Cancer/Gastroesophageal Junction Cancer
This clinical trial update summarizes a retrospective evaluation of nivolumab as adjuvant therapy for esophageal cancer and gastroesophageal…
-
CLINICAL_TRIALS trial_result · 2025-05-30Clinical Trial Update: Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore [Phase 2]
Phase 2 clinical trial assessing first-line treatment with lenvatinib plus tislelizumab and CapeOX for advanced gastric/gastroesophageal jun…
-
CLINICAL_TRIALS trial_result · 2025-05-16Clinical Trial Update: A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer
A completed clinical trial evaluating PET imaging with the radiotracer 18F-BMS-986229 in patients with cancers of the esophagus, stomach, or…
-
CLINICAL_TRIALS trial_result · 2025-05-06Clinical Trial Update: A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer [Phase 1, Phase 2]
A phase 1/2 study evaluating CAM-H2, a HER2-directed radioligand, in advanced/metastatic HER2-positive breast, gastric, and gastroesophageal…
-
CLINICAL_TRIALS trial_result · 2025-04-22Clinical Trial Update: Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer [Phase 2, Phase 3]
This clinical trial update reports the completion of a Phase 2/3 study evaluating a four-drug combination (margetuximab, retifanlimab, tebot…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-03-30Clinical Trial Update: A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer [Phase 3]
Phase 3 trial of SHR1701 plus chemotherapy for gastric or gastroesophageal junction cancer is currently active but not recruiting.
-
CLINICAL_TRIALS trial_result · 2025-03-27Clinical Trial Update: OPPOSITE: Outcome Prediction of Systemic Treatment in Esophagogastric Carcinoma [NA]
Clinical trial OPPOSITE, studying outcome prediction of systemic treatment in esophagogastric carcinoma, has completed. The sponsor is Unive…
-
CLINICAL_TRIALS trial_result · 2025-02-20Clinical Trial Update: Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension [Phase 3]
This is the China extension of the Phase 3 KEYNOTE-585 trial evaluating pembrolizumab plus chemotherapy versus placebo plus chemotherapy in …
-
CLINICAL_TRIALS trial_result · 2025-02-20Clinical Trial Update: Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) [Phase 3]
A Phase 3 trial (MK-3475-585/KEYNOTE-585) evaluating pembrolizumab plus chemotherapy versus chemotherapy alone in gastric cancer and gastroe…
-
CLINICAL_TRIALS trial_result · 2025-02-14Clinical Trial Update: Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma [Phase 3]
Phase 3 trial evaluated tislelizumab in combination with chemotherapy as first-line treatment for adults with inoperable, locally advanced o…
-
CLINICAL_TRIALS trial_result · 2025-02-10Clinical Trial Update: A Study of SGN-ALPV in Advanced Solid Tumors [Phase 1]
Seagen's Phase 1 study of SGN-ALPV in advanced solid tumors has been terminated; the trial evaluated multiple cancers including ovarian, end…
-
CLINICAL_TRIALS trial_result · 2024-12-12Clinical Trial Update: CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma [Phase 1, Phase 2]
The clinical trial of CYNK-101 in combination with trastuzumab and pembrolizumab for HER2-positive gastric or gastroesophageal junction canc…
-
CLINICAL_TRIALS trial_result · 2024-12-06Clinical Trial Update: Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab [Phase 1, Phase 2]
Zanidatamab (ZW25) in combination with chemotherapy, with or without tislelizumab, is being evaluated in Phase 1/2 trials for breast cancer,…
-
CLINICAL_TRIALS trial_result · 2024-12-02Clinical Trial Update: A Study of IMAB362 in Japanese Subjects With Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma [NA]
Clinical trial update for IMAB362 (zolbetuximab) in Japanese patients with locally advanced or metastatic gastric or GEJ adenocarcinoma; the…
-
CLINICAL_TRIALS trial_result · 2024-11-12Clinical Trial Update: Mecapegfilgrastim Combined With Adebrelimab and Chemotherapy as Neoadjuvant Therapy in Resectable GC/GEJC [Phase 2]
A Phase 2 clinical trial is evaluating mecapegfilgrastim combined with adebrelimab and chemotherapy as neoadjuvant therapy for resectable ga…
-
CLINICAL_TRIALS trial_result · 2024-10-23Clinical Trial Update: BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma [Phase 2]
Phase 2 trial evaluating BGB-A317 in combination with chemotherapy as first-line treatment for adults with inoperable, locally advanced, or …
-
CLINICAL_TRIALS trial_result · 2024-10-21Clinical Trial Update: Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating a Cadonilimab-based combination as first-line therapy for metastatic HER2-expressing gastric or gas…
-
CLINICAL_TRIALS trial_result · 2024-10-18Clinical Trial Update: A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating sitravatinib as monotherapy and in combination with tislelizumab in participants with unresectable loc…
-
CLINICAL_TRIALS trial_result · 2024-10-10Clinical Trial Update: Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma [Phase 2]
Phase 2 trial evaluating safety and efficacy of telatinib in combination with pembrolizumab in advanced gastric cancer, gastroesophageal jun…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: The Efficacy and Safety of LM-302 in Combination With Candonilimab and Capecitabine for First-Line Treatment in Patients With Unresectable Advanced, Recurrent, or Metastatic CLDN18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma [Phase 2]
A Phase 2 clinical trial evaluating LM-302 with Candonilimab and capecitabine as first-line therapy for CLDN18.2-positive gastric or GEJ ade…
-
CLINICAL_TRIALS trial_result · 2024-08-16Clinical Trial Update: NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma [Phase 1]
A Phase 1 trial of NT-I7 in combination with nivolumab for advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma has bee…
-
CLINICAL_TRIALS trial_result · 2024-06-04Clinical Trial Update: A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma [Phase 2]
A Phase 2 study evaluating niraparib in previously treated metastatic esophageal, gastroesophageal junction, and proximal gastric adenocarci…
-
CLINICAL_TRIALS trial_result · 2024-05-17Clinical Trial Update: Safety and Efficacy of Pembrolizumab in Combination With FLOT About Gastroesophageal Junction Cancer: [Phase 3]
Phase 3 clinical trial evaluating pembrolizumab in combination with the FLOT chemotherapy regimen for gastroesophageal junction cancer; the …
-
CLINICAL_TRIALS trial_result · 2024-05-14Clinical Trial Update: JNT Versus TNT to Guided OGT-overlap Oesophagojejunostomy [NA]
A completed clinical trial comparing JNT versus TNT methods to guide OGT-overlap oesophagojejunostomy in gastric and gastroesophageal juncti…
-
CLINICAL_TRIALS trial_result · 2024-03-12Clinical Trial Update: KN026 in Patients With HER2 Expressing Gastric/Gastroesophageal Junction Cancer [Phase 2]
Phase 2 clinical trial update for KN026 in patients with HER2-expressing gastric/gastroesophageal junction cancer; study status completed.